Actively Recruiting
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2026-02-12
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying children and adults with idiopathic interstitial pneumonias, progressive fibrosing interstitial pneumonias, interstitial pneumonia linked to Scleroderma, and patients with mutations in telomere-related genes. This national, observational, longitudinal, multicenter study aims to gather consistent clinical data from these patients and their relatives, whether or not they carry the mutations. The study will last about 10 years, including 5 years of participant enrollment and 5 years of follow-up plus data analysis. The study collects medical data retrospectively and prospectively at specific intervals: at 6 months to 1 year after enrollment, then at least once yearly for patients up to 5 years, and for their relatives at inclusion and 5 years later. Participants will complete questionnaires during regular follow-up visits or through a secure online system. Various clinical assessments will be recorded, including respiratory exams, imaging scans, biological samples, lung function tests, cardiac evaluations, skin and fertility assessments, bone density, and treatments. During the study, participants will undergo comprehensive evaluations such as chest scans, echocardiography, bronchoscopy, lung biopsies when available, and laboratory tests. Data on genetics, environmental factors, biomarkers, immune and liver function, cancer history, and more will also be collected. These assessments will occur at regular intervals up to 5 years for patients and relatives. This extensive monitoring helps researchers understand disease progression and related factors over time.
CONDITIONS
Brief Title
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of idiopathic interstitial pneumonia based on clinical, radiological, or functional criteria
- Confirmed diagnosis of non-IPF progressive fibrotic interstitial lung disease with fibrosis ≥ 10% on CT scan and disease progression despite appropriate management
- Confirmed diagnosis of systemic sclerosis-associated interstitial lung disease meeting American College of Rheumatology criteria with disease extent ≥ 10% on high-resolution CT scan
- First-degree relatives of patients carrying mutations in telomere-related genes such as TERT, TERC, RTEL1, TINF2, DKC1, PARN, or others included in the study
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed over several years with regular clinical examinations and various assessments to monitor their lung and overall health.
Visits at inclusion, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years
Trial Site Locations
Total: 1 location
1
RaDiCo-ILD2
Paris, Île-de-France Region, France, 75012
Actively Recruiting
Research Team
V
Vincent Cottin, Pr
A
Annick Clement, Pr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here